HIV and AIDS Articles on:
| |
FDA-approved
Treatments Experimental
Treatments
Top
New Articles |  |
Gilead
and Boehringer Freeze Prices on Viread and Truvada to U.S. Agencies
Gilead will suspend price increases of Viread and Truvada to three U.S. and state government agencies through December 31, 2010, according to the AHF. Boehringer will freeze the price of Aptivus for state AIDS programs through May 1, 2009, according to AHP. AHF has requested that companies suspend price increases because of difficulties government programs have had in expanding access to life-saving AIDS drugs, the organization said. Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Roche, and Tibotec Therapeutics units didn't agree to the AHF request, the foundation said in an email. ``We urge the other drug companies to follow Boehringer's and Gilead's lead and to freeze price increases that create an unnecessary burden on an already overburdened public health system and keep lifesaving drugs out of reach for those who need them,'' said Michael Weinstein, president of AHF. About 3 million patients in low- and middle-income countries are receiving effective AIDS treatment today, about one- third more than in 2006, according to the World Health Organization (WHO). About 33 million people worldwide are infected with HIV worldwide, WHO reports. U.S. Agencies Benefitting from Price Freeze Gilead will freeze prices on Viread and Truvada for the U.S. Public Health Service, the Federal Supply Service, and the state AIDS Drug Assistance Programs, Gilead's Amy Flood told Bloomberg.com. Worldwide sales of Gilead's AIDS drugs last year totaled $3.14 billion, she said. ``We share your concern regarding antiretroviral cost pressures face by government payers, particularly during times of limited budget access and flat funding,'' said Gregg Alton, senior vice president and general counsel for Gilead, in a letter to the AHF. Boehringer has already reduced the price of Viramune (nevirapine) to 60 cents a day in 78 low-income countries, and $1.20 a day in 67 middle-income countries, company officials said in a letter to the AHF. The price freeze on Aptivus will apply to sales to state AIDS Drug Assistance Programs, and became effective May 1. 6/06/08 Source
| |||||||||||||
| |||
Protease
Inhibitors (PIs) Note: Most PIs are now used in combination with low-dose ritonavir (Norvir) | |||
 | Agenerase (amprenavir) | ||
 | Aptivus (tipranavir) | ||
 | Crixivan (indinavir) | ||
 | Invirase (saquinavir ) | ||
 | Kaletra (lopinavir/ritonavir) | ||
 | Lexiva (fosamprenavir) | ||
 | Norvir (ritonavir) | ||
 | Prezista (darunavir) | ||
 | Reyataz (atazanavir) | ||
 | Viracept (nelfinavir) | ||
Nucleoside
/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs) | |||
 | Combivir (zidovudine + lamivudine) | ||
 | Epivir (lamivudine; 3TC) | ||
 | Emtriva (emtricitabine; FTC) | ||
 | Epzicom (abacavir + lamivudine) | ||
 | Retrovir (zidovudine; AZT) | ||
 | Trizivir (abacavir + zidovudine +lamivudine) | ||
 | Truvada (tenofovir + emtricitabine) | ||
 | Videx (didanosine; ddI) | ||
 | Viread (tenofovir) | ||
 | Zerit (stavudine; d4T) | ||
 | Ziagen (abacavir) | ||
non
Nucleoside Reverse Transcriptase Inhibitors (nNRTIs) | |||
 | Intelence (etravirine) | ||
 | Rescriptor (delavirdine) | ||
 | Sustiva (efavirenz) | ||
 | Viramune (nevirapine) | ||
Entry
/ Fusion Inhibitors | |||
 | Fuzeon (enfuvirtide) | ||
 | Selzentry/Celsentri ( maraviroc) | ||
Fixed-dose
Combinations | |||
 | Atripla (efavirenz + emtricitabine + tenofovir) | ||
| Combivir (zidovudine + lamivudine) | ||
| Trizivir (abacavir + zidovudine + lamivudine) | ||
| Truvada (tenofovir + emtricitabine) | ||
Integrase
Inhibitors | |||
 | Isentress (raltegravir) | ||
| |||
